In a large Chinese cohort of 977 screened NSCLC patients, four out of 13 of the cases identified with EGFR/ALK co-alterations responded only to either an EGFR-TKI or an ALK-TKI at different time points, suggesting that one of these oncogenes might have had a dominant impact in these four cases [128]. This evidence concerns the gene ALK and non-small cell lung carcinoma.